GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark receives 'India Pharma Innovation of the Year' Award from the Govt. of India25-02-2021
25-02-2021
Glenmark arm gets Russian Health Ministry nod for nasal spray Ryaltris
Glenmark Pharmaceuticals on Monday said its Swiss subsidiary has received marketing approval from the Russian health regulator for its nasal spray Ry22-02-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark's Ryaltris(r)- innovative single nasal spray, ready to market in Russia22-02-2021
Buy Glenmark Pharmaceuticals; target of Rs 635: ICICI Direct
ICICI Direct is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 635 in its research report dated February 15, 2021.17-02-2021
Asset monetisation, sales uptick in US key triggers for Glenmark Pharma
The India business is expected to post double digit growth in FY2216-02-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark launches SUTIB (Sunitinib) - priced 96% lower than the innovator brand. Reduces the risk of kidney cancer progression by 58%16-02-2021
Earnings Call for Q3FY21 of Glenmark Pharmaceuticals
Conference Call with Glenmark Pharmaceuticals Management and Analysts on Q3FY21 Performance and Outlook. Listen to the full earnings transcript.15-02-2021
Glenmark Q3 net profit rises 30% at Rs 248.17 crore
The company had posted a net profit of Rs 190.83 crore for the corresponding period of the previous fiscal.13-02-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Outcome Of The Board Meeting Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 To Consider Repurchase Of Foreign Currency Debt
We hereby inform you that, pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, the Board of Directors of Glenmark Pharmaceuticals Limited ("Company") at its meeting held on February 12, 2021, which commenced at 5:30 p.m. and concluded at 9:20 p.m., have considered and approved opportunistic tenders or buybacks of any part of its Singapore listed foreign currency convertible bonds, being, its U.S.$200 million (as on date outstanding U.S.$ 113.5 million) 2 per cent resettable onward starting equity linked securities due 28 June 2022 issued in 2016 ("FCC Bonds") by the Company. ("Bond Repurchase"), based on market opportunities and conditions from time to time.12-02-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Unaudited Financial Results (Standalone And Consolidated) For The Third Quarter And Nine Months Ended December 31, 2020
Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2020. The said meeting of the Board commenced at 5.30 p.m. and concluded at 9.20 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarkpharma.com12-02-2021